Halozyme Names David Ramsay Interim Chief Financial Officer

Halozyme ( (HALO) ) has provided an announcement.

On March 12, 2026, Halozyme Therapeutics announced the appointment of David Ramsay as Interim Chief Financial Officer, effective March 23, 2026, tasking the veteran finance executive with overseeing all financial operations while the company completes its search for a permanent CFO. Ramsay, who previously served as Halozyme’s CFO during its evolution into a billion‑dollar public biopharmaceutical company, brings more than three decades of biotechnology and life‑sciences finance experience, and his compensation package includes a $50,000 monthly salary and time‑based restricted stock units that further align his interests with shareholders.

Halozyme’s leadership highlighted Ramsay’s prior role in building the company’s financial and commercialization infrastructure and emphasized his capital markets and investor relations expertise as critical to advancing current strategic priorities. The board has engaged an executive search firm to identify a long‑term finance chief, while Ramsay’s return is expected to provide continuity and credibility with investors and partners during the transition period.

The most recent analyst rating on (HALO) stock is a Hold with a $75.00 price target. To see the full list of analyst forecasts on Halozyme stock, see the HALO Stock Forecast page.

Spark’s Take on HALO Stock

According to Spark, TipRanks’ AI Analyst, HALO is a Outperform.

The score is driven primarily by strong financial performance—especially cash flow strength and scaled revenue growth—tempered by balance-sheet thinness and a step-down in profitability vs. 2024. Technicals add moderate support (positive longer-term trend with cooling near-term), while valuation is a modest headwind given the ~29 P/E. Earnings-call guidance and pipeline momentum are supportive but balanced by acquisition/litigation-related cost and uncertainty.

To see Spark’s full report on HALO stock, click here.

More about Halozyme

Halozyme Therapeutics, Inc. is a San Diego‑based biopharmaceutical company focused on drug delivery technologies and drug‑device combination products that improve patient experiences and treatment convenience. Its flagship ENHANZE drug delivery platform, based on the proprietary rHuPH20 enzyme, enables subcutaneous administration of biologics and is licensed to major global pharma partners, while additional Hypercon and Surf Bio hyperconcentration technologies and auto‑injector products broaden its presence across multiple therapeutic modalities and markets.

The company also markets proprietary products such as Hylenex and XYOSTED and supports partnered commercial programs and development collaborations with large biopharmaceutical firms. Halozyme operates facilities and offices in California, New Jersey, Minnesota and Massachusetts, positioning it as a key infrastructure and technology provider within the injectable biologics and drug‑device combination ecosystem.

Average Trading Volume: 1,881,983

Technical Sentiment Signal: Buy

Current Market Cap: $7.85B

See more data about HALO stock on TipRanks’ Stock Analysis page.